Oct. 13 (Thu.) ,2016 14:15-15:15

Annex Hall
F201

Public Institution

Simultaneous Interpretation

EFPIA Japan

Frontline of Open Innovation

IMI (Innovative Medicine Initiative) is joint undertaking of EFPIA and EU which invest 52 billion Euro in total for open innovation, public private partnership projects.Through this seminar, we will explore current achievement of IMI and the latest progress of IMI. In addition, we will look into collaborative drug development project both in EU (ELF: European Lead Factory) and Japan (AMED’s support of innovative drug discovery and development). In addtion, at the panel discussion, we will learn difference and similarity of collaborative drug development projects from EU and Japan to find out best practices.

Cordinator

Dr. Masuhiro Kato

Project Professor, Translational Research Initiative, The Tokyo University

The Latest Development of Innovative Medicine Initiative (IMI)

Dr. Matthias Gottwald

Head of R&D Policy and Networking, Global External Innovation & Alliances, Bayer Pharma AG / Chair of IMI Operations Group, EFPIA

Collaborative Drug Development in Europe: European Lead Factory

Dr. Matthias Gottwald

Head of R&D Policy and Networking, Global External Innovation & Alliances / Project lead of European Lead Factory, Bayer Pharma

Collaborative Drug Development in Japan: Case of AMED

Dr. Toru Takashi

Manager, East Japan, Dept. of Innovative Drug Discovery and Development, , Japan Agency for Medical Research and Development

Close Window